Study Details

Back
Study ID OSI-774-108
Study Title A Phase 1b Study of Erlotinib in Combination with Gemcitabine and nab-Paclitaxel in Patients with Previously Untreated Advanced Pancreatic Cancer
Clinicaltrials.gov Identifier NCT01010945
Compound Name OSI-774 / erlotinib
Medical Indication or Disease Pancreatic cancer
Study Sponsor Astellas Pharma Global Development, Inc. on behalf of OSI Pharmaceuticals, LLC
Collaborator Not Applicable
Study Start Date 03-Feb-2010
Study Completion Date 25-Jan-2012
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS